23 May 2013
Keywords: merck, kgaa, gsk, drop, antidepressant, novel, development
Article | 28 April 2003
A novel antidepressant in development at Merck KGaA and GlaxoSmithKlinehas been dropped from development after disappointing results in a Phase
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
28 April 2003
10 March 2003
17 March 2003
© 2013 thepharmaletter.com